Dynamic Technology Lab Private Ltd Invests $238,000 in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Dynamic Technology Lab Private Ltd bought a new stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) in the 3rd quarter, Holdings Channel.com reports. The fund bought 19,894 shares of the company’s stock, valued at approximately $238,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD grew its position in shares of Olema Pharmaceuticals by 6.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 26,251 shares of the company’s stock valued at $298,000 after purchasing an additional 1,486 shares during the last quarter. California State Teachers Retirement System grew its holdings in Olema Pharmaceuticals by 3.4% during the 1st quarter. California State Teachers Retirement System now owns 34,695 shares of the company’s stock valued at $393,000 after buying an additional 1,132 shares during the last quarter. Hennion & Walsh Asset Management Inc. purchased a new position in Olema Pharmaceuticals during the second quarter worth $945,000. Bank of New York Mellon Corp raised its holdings in shares of Olema Pharmaceuticals by 72.1% in the second quarter. Bank of New York Mellon Corp now owns 139,923 shares of the company’s stock worth $1,514,000 after acquiring an additional 58,622 shares during the last quarter. Finally, Rhumbline Advisers lifted its position in shares of Olema Pharmaceuticals by 43.5% in the second quarter. Rhumbline Advisers now owns 59,261 shares of the company’s stock valued at $641,000 after acquiring an additional 17,953 shares in the last quarter. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

OLMA has been the subject of a number of recent research reports. Oppenheimer reiterated an “outperform” rating and set a $30.00 price objective on shares of Olema Pharmaceuticals in a research report on Wednesday, August 7th. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Olema Pharmaceuticals in a research report on Wednesday, November 13th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Olema Pharmaceuticals from $33.00 to $31.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Olema Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $27.00.

Olema Pharmaceuticals Price Performance

OLMA opened at $10.12 on Monday. Olema Pharmaceuticals, Inc. has a 12 month low of $7.68 and a 12 month high of $16.77. The business has a 50-day moving average of $11.30 and a two-hundred day moving average of $11.90. The stock has a market capitalization of $579.86 million, a price-to-earnings ratio of -4.62 and a beta of 2.02.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.